Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.
Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.
Margery Gass, MD, led a 12-week, randomized study at George Washington University comparing lasofoxifene to placebo. Dr. Gass said the results clearly show the benefits of the drug.
At baseline, moderate to severe symptoms of dyspareunia were reported by 73% of all women in the study and 92% of sexually active women. After 12 weeks, women taking 0.25 mg/day of lasofoxifene showed a 1.2 decrease in their dyspareunia symptom score. Women receiving 0.5 mg/d showed a drop of 1.5. Women in the placebo arm showed a drop of 0.9 in their symptom score (P=0.056 and 0.018, respectively).
Vaginal bleeding was rare in all three groups and there were no differences in the percentage of women experiencing vaginal bleeding between any of the three groups. Lasofoxifene is the first elective estrogen receptor modulator to show a beneficial effect on dyspareunia.
Simon J, Gass M, Kagan R, Spino C, Nemeth MA. Lasofoxifene effectively treats dyspareunia in postmenopausal women with vaginal atrophy. Obstet Gynecol. 2005;105(4 suppl):2S.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More